Shamburg News · 8-K filed Nov 12, 2026, 7:16 AM EST

Century Therapeutics Reports Third Quarter 2026 Results; Net Loss of $23.5 Million

IPSC · Century Therapeutics, Inc.

  • Earnings
  • Leadership change
  • Financial statements
  • Materiality: high

Century Therapeutics furnished a press release reporting financial results for the quarter ended September 30, 2026, under Item 2.02. The company reported a net loss of $23.5 million for the quarter, compared with a net loss of $34.4 million a year earlier, and cash, cash equivalents and investments of $174.1 million as of September 30, 2026. The release also announced the appointment of Joseph Truitt to the Board of Directors and reiterated plans for a CNTY-813 IND submission in 4Q 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001104659-26-125830.

Written from the filing by Shamburg Markets. Figures are as reported by the company.